|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 9/16 | (2006.01) |
| A61K 9/20 | (2006.01) | ||
| A61K 9/28 | (2006.01) | ||
| A61K 31/506 | (2006.01) |
| (11) | Number of the document | 1885339 |
| (13) | Kind of document | T |
| (96) | European patent application number | 06769997.5 |
| Date of filing the European patent application | 2006-05-04 | |
| (97) | Date of publication of the European application | 2008-02-13 |
| (45) | Date of publication and mention of the grant of the patent | 2015-07-29 |
| (46) | Date of publication of the claims translation | 2015-11-25 |
| (86) | Number | PCT/US2006/017073 |
| Date | 2006-05-04 |
| (87) | Number | WO 2006/121742 |
| Date | 2006-11-16 |
| (30) | Number | Date | Country code |
| 678030 P | 2005-05-05 | US |
| (72) |
GAO, Julia ZH, US
MOTHERAM, Rajeshwar, US
|
| (73) |
Bristol-Myers Squibb Holdings Ireland Unlimited Company,
Hinterbergstrasse 16, 6312 Steinhausen,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Src/Abl inhibitoriaus farmacinės kompozicijos |
| FORMULATIONS OF A SRC/ABL INHIBITOR |
| Payment date | Validity (years) | Amount | |
| 2021-04-21 | 16 | 347.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2021-05-10 |